I agree that the regulators are crucial. In my opinion, the FDA and NIH are quite significant and NIH support for Dr. Liau’s work is noteworthy. The NIH has supported Liau’s work for 20 consecutive years.
9/14/2022 In a trial now underway, a dendritic cell vaccine is made from a participant's own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.
"What I'm excited about is that we're seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations," Dr. Liau says. "We're seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we're trying to find out what combination works best and for which patients."
The NIH is largely responsible for the development of the murcidencel cell-based platform technology as they have always supported and funded Liau’s research. The 20 consecutive years of NIH funding of Dr. Liau have played a direct and crucial role in murcidencel. Together with Merck, NIH is funding the murcidencel doses going into arms TODAY in a study investigating its efficacy in combo with pembrolizumab.
" It's how the publication game works. They get author credit without having to write the article. "
For someone, maybe everything is just a game. But for a lot of conscionable scientists and neurosurgeons who hold the Hippocratic oath, it is a serious issue between life and death. Saying it is just a game is a flagrant insult on those who coauthored the paper.